Table 4.
Final estimates of population pharmacokinetic parameters for amikacin and Bootstrap validation of the estimated population pharmacokinetic parameters in the final model
| Parameter | Final estimates | Bootstrap mean ± SD | Median [95% CI] | Difference (%) |
|---|---|---|---|---|
| θ 1 (L/h) | 2.41 | 2.54 ± 0.38 | 2.50 [1.97–3.31] | 5.39 |
| θ 2 (L) | 10.70 | 10.20 ± 2.29 | 10.26 [5.99–14.69] | −4.67 |
| Intra-individual | ||||
| ω (CL) (%) | 50.8 | 46.4 ± 36.8 | 44.7 [18.4–55.7] | −8.66 |
| ω (V 1) (%) | 29.0 | 37.0 ± 35.8 | 31.9 [27.2–65.6] | 27.6 |
| Intra-individual | ||||
| σ (μg/mL) | 0.25 | 0.20 ± 0.09 | 0.23 [0.01–0.33] | −20.0 |
Successful rate of calculation = 100% (200/200). Final model: CL (L/h) = θ 1(CCr/60.0), V1 (L) = θ 2(weight/49.5), V 2 (L) = 7.72, Q (L/h) = 7.0. Bootstrap validation of the estimated population pharmacokinetic parameters in the final model. The difference between the final model estimate and bootstrap mean is calculated as follows: [(bootstrap mean − final model estimate)/final model estimate] × 100
CCr creatinine clearance, CI confidence interval, CL total body clearance, Q inter-compartmental clearance, SD standard deviation, V 1 volume of distribution in the central compartment, V 2 volume of distribution in the peripheral compartment